The effects of telmisartan treatment on the abdominal fat deposit in metabolic syndrome combined with essential hypertension
10.3760/cma.j.issn.1673-4904.2014.01.010
- VernacularTitle:替米沙坦对代谢综合征合并高血压患者内脏脂肪沉积的影响
- Author:
Ying HUANG
;
Jianchang LU
;
Lixin ZHOU
;
Gaozhong LI
;
Fang WU
- Publication Type:Journal Article
- Keywords:
Metabolic syndrome X;
Hypertension;
Adipose tissue;
Telmisartan;
Valsarta
- From:
Chinese Journal of Postgraduates of Medicine
2014;37(1):30-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of telmisartan treatment on the abdominal fat deposit in metabolic syndrome (MS) combined with essential hypertension (EH).Methods Sixty patients of MS combined with EH were divided into two groups according to random number table method,with 30 cases in each group.The patients in experimental group were given telmisartan orally 40 mg once a day,and in control group were given valsartan 80 mg once a day,until average ambulatory blood pressure monitoring blood pressure was ＜ 140/90 mmHg (1 mmHg =0.133 kPa) in 24 weeks.The visceral fat area (VFA) and subdermal fat area (SFA) was measured by multislice CT,at the same time the body mass index (BMI),blood pressure,blood glucose,homeostasis model assessment of insulin resistance (HOMA-IR) and glyeosylated hemoglobin (HbA1c) of the subjects was measured.Results The blood pressure,BMI,blood glucose,HbA1c,and blood lipids between two groups before treatment had no statistical significance (P ＞0.05).VFA in experimental group after treatment was lower than that before treatment [(127.8 ± 16.6) cm2 vs.(150.5 ± 15.4) cm2] (P ＜ 0.05).But there was no statistical significance of VAF in control group before and after treatment (P ＞0.05).The SFA in experimental group and control group had no statistical significance before and after the treatment (P ＞ 0.05).The HOMA-IR in experimental group after treatment was reduced compared with that before treatment (1.9 ± 0.3 vs.4.2 ± 0.9),and adiponectin was increased [(5.77 ±0.71) mg/L vs.(3.16 ±0.72) mg/L] (P ＜0.05).Conclusion Compared with valsartan,telmisartan can significantly reduce the visceral fat deposition in MS combined with EH patients and improve insulin resistance.
